By IDSE News Staff
The new chikungunya vaccine, recombinant (Vimkunya, Bavarian Nordic A/S), the first virus-like particle (VLP) single-dose, prefilled syringe vaccine approved by the FDA, is now available, the company announced.
The vaccine for use in people 12 years of age and older is the first chikungunya vaccine to leverage VLP technology, using VLPs designed to mimic the chikungunya virus (CHIKV) without the ability to infect cells, replicate or cause disease.